The Board of Directors of QuickCool AB (publ) (the "Company") currently negotiates various financing options and different arrangements. Earlier an RTO proposal within the cannabis and other alternative medical markets was discussed, but this proposal was withdrawn on 24 November, 2019. It is no longer an alternative to invest in the cannabis and other alternative medical market. The Board discusses and negotiates different available options. During the month of February, the Board of Directors will present and propose a long-term financing solution.

Lund 07 February 2020
QuickCool AB (publ)
The Board of Directors

For more information, please contact:
Fredrik Radencrantz, CEO
Phone: 046-286 38 40
E-mail: fredrik.radencrantz@quickcool.se

This information is such that QuickCool AB is required to make public in accordance with the EU's market abuse regulation (MAR). The information was made publicly available by the Company's contact person on 07 February 2020.
 

Quickcool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the Quickcool SYSTEM. Quickcool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool's solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool's Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. Quickcool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se